Empowering innovative science and transformativetherapeutics

Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).

Aelix Therapeutics is a clinical-stage company developing a vaccine to treat HIV infection. The company is a spin-off of HIVACAT.

Anaconda BioMed, headquartered in Barcelona, Spain, is among the world’s most innovative early stage medical technology companies.

Aura Biosciences is applying nanotechnology to the fight against cancer. Its novel viral nanoparticle technology, developed in partnership with the National Cancer Institute (NCI), harnesses the potential of viral evolution and tumor targeting for the treatment of cancer.

BioVex was a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease using oncolytic viruses.

CorWave is a French medtech company developing next-generation blood pumps for heart failure patients.

CVRx® developed a proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim neo uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. Barostim neo can be adjusted to meet each patient’s individual therapy needs.

CytoKi Pharma is a biotechnology company engaged in the development of protein drugs for diseases characterized by epithelial injury, with focus on developing a licensed long-acting IL-22 program for Inflammatory Bowel Disease and potentially additional clinical indications.

Endosense was a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias.

Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and cancer based on targeting galectins, a group of proteins shown to be involved in many disease processes. Galecto’s team of scientists and experts has shown in preclinical and clinical studies that the company’s high potency galectin modulators may open new treatment possibilities for many patients. The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen, Denmark.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary mucus-penetrating particle technology, with a focus on the treatment of eye diseases. Kala’s first product, INVELTYS® for the treatment of inflammation and pain following ocular surgery, was approved in 2019 and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease is in phase III trials

LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.

Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.

Minoryx is a clinical-stage biotech company developing new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program leriglitazone (MIN-102) has completed a Phase II/III clinical trial for the treatment of adrenomyeloneuropathy, the most common phenotype of X-linked Adrenoleukodystrophy, and a Phase II study in Friedreich’s Ataxia.

NorthSea Therapeutics is a Clinical-stage biotech company with the aim to develop novel and innovative therapeutic strategies for NASH and other metabolic, inflammatory and fibrotic diseases.

Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism

Sanifit is a clinical-stage biopharmaceutical company focused on the development of SNF472, an experimental drug for the treatment of cardiovascular diseases linked to calcification in the end-stage renal disease population undergoing haemodialysis.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases.

STAT-DX was developin near-patient testing products for healthcare professionals with short turnaround time applications and critical care.

Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS)

Initial investment in Cellerix, founded in 2004. Cellerix was a biopharmaceutical company developing innovative treatments based on a cell therapy. Subsequently it reverse-merged with Tigenix listed on Euronext. Tigenx was Acquired in July 2018 by Takeda Pharmaceuticals.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases including Wilson Disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and other indications. Vivet is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression.